Background: Olumacostat glasaretil (OG) inhibits acetyl-coenzyme A carboxylase, the enzyme responsible for the first, rate-limiting step in de novo fatty acid synthesis. OG inhibited in vitro human sebocyte lipid production and reduced in vivo sebaceous gland size in hamster ears.
A cne arises from multiple physiologic changes in the skin: altered keratinocyte differentiation, increased sebum production, bacterial colonization by Propionibacterium acnes, and inflammation. 1 targeting. A direct correlation exists between acne improvement and sebum reduction induced by oral antiacne medications, including isotretinoin. 3 In contrast, there are no topical agents that significantly affect sebum production. 4, 5 A topical medication that selectively and safely inhibits sebum production could represent an important advance in acne treatment.
Acetyl-coenzyme A (CoA) carboxylase catalyzes the carboxylation of acetyl-CoA to form malonyl-CoA, the first committed, rate-limiting step in fatty acid biosynthesis. [6] [7] [8] Malonyl-CoA also increases mitochondrial fatty acid uptake and oxidation. 9 Inhibition of malonyl-CoA synthesis offers a means to inhibit de novo fatty acid production in sebaceous glands (Fig 1) .
Olumacostat glasaretil (OG) (formerly DRM01), a prodrug, is hydrolyzed by esterases in vivo to form the pharmacologically active moiety 5-(tetradecyloxy)-2-furancarboxylic acid, which converts to 5-tetradecyloxy-2-furoyl-CoA, a fatty acid mimetic that competes with acetyl-CoA, thus inhibiting formation of malonyl-CoA. 10 This article describes the safety and efficacy of OG in a first-in-man study in adults with acne vulgaris.
METHODS

Study design
This phase IIa, randomized, double-blind, vehicle-controlled, parallel-group study was conducted at 12 centers in Canada from August 7, 2013, through June 3, 2014, in adults with moderate to severe facial acne vulgaris. The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The study was approved by an institutional review board or ethics committee at each participating site. The study was registered at ClinicalTrials.gov, identifier NCT01936324.
Patients were randomized (1:1) to receive OG or placebo vehicle using a computer-based randomization program. Patients applied the assigned treatment to the face twice daily for 12 weeks. During treatment, the patient's skin care was to remain stable, and patients were to avoid other acne treatments, facial procedures, and excessive sun exposure.
Efficacy was assessed through acne lesion counts and the investigator global assessment (IGA) scale.
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These parameters were evaluated before the first dose of study drug (baseline) and at weeks 4, 12 (end of treatment), and 16 (follow-up). The IGA scoring criteria consisted of a 5-point scale, ranging from 0 (clear skin) to 4 (severe acne).
Safety assessments were monitored routinely. Serum chemistries, hematology, and urinalysis were performed at screening and week 12; vital signs and local skin reactions (erythema, dryness, peeling, burning/stinging, and pruritus) were evaluated at each clinic visit. Local skin reaction severity was scored on a 4-point scale (0, no reaction; 3, severe reaction).
Participant eligibility and requirements
Eligible patients were men and women aged 18 years or older, in good health, with a clinical diagnosis of facial acne vulgaris, 20 or more inflammatory lesions, 20 or more noninflammatory lesions, and an IGA score of 3 or more. Patients were required to use birth control during the study and for 30 days after the last application of study drug. Hormonal therapy (eg, birth control pills) was allowed if the patient was on a stable regimen for 12 or more weeks before study initiation.
Patients were excluded if they had skin conditions that would interfere with acne assessments; active cystic acne, acne conglobata, acne fulminans, or secondary acne; 2 or more active nodular lesions; or prior use of an androgen receptor blocker.
Patients were not to have used oral retinoids for at least 12 months before study initiation, nor vitamin A supplements more than 10,000 U/d for at least 6 months. Systemic corticosteroids, antibiotics, antiacne drugs, anti-inflammatory drugs, prescription topical retinoids, and any investigational drugs were not permitted within 4 weeks before the study. Overthe-counter topical medications for acne were not permitted within 2 weeks before the study; and facial procedures were not allowed within 8 weeks before the study.
End points
The primary efficacy end points were: change in inflammatory lesion and noninflammatory lesion
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counts from baseline at week 12; and the proportion of patients with a minimum 2-grade improvement in IGA score at week 12. Secondary efficacy end points included evaluation of the primary end points at weeks 4 and 16; and the percent change in lesion count from baseline to weeks 4, 12, and 16.
Statistical analysis
The sample size of 100 patients was based on clinical considerations only.
Efficacy analyses were based on the intent-to-treat population, ie, all randomized patients who were dispensed study drug. Changes from baseline to week 12 in inflammatory and noninflammatory lesion counts were analyzed separately using an analysis of covariance model with terms for baseline value, treatment, and center; treatment-by-center interaction was excluded from the model because it was not significant at the prespecified 0.1 level of significance. The proportion of patients with greater than or equal to 2-grade improvement from baseline to week 12 in IGA score was analyzed using the Cochran-Mantel-Haenszel test stratified by center. Missing data were imputed using the last available on-treatment observation to estimate subsequent missing data points.
The safety population was prospectively defined as all randomized patients who applied at least 1 dose of study drug.
RESULTS
In all, 108 patients with moderate to severe facial acne were enrolled; 53 were randomized to OG treatment and 55 to vehicle treatment (Fig 2) . Demographic and baseline characteristics appeared similar between groups (Table I) . Overall, 97 patients completed the study; 6 patients in the OG group and 5 in the vehicle group discontinued early because of: withdrawal of consent (3 patients in the OG group and 4 in the vehicle group), applicationsite adverse events (AEs) (2 patients in the OG group), pregnancy (1 patient in the OG group), and acne worsening (1 patient in the vehicle group).
Compliance was approximately 98% in both groups.
At week 12, patients in the OG group had statistically significantly greater reductions in both inflammatory and noninflammatory lesion counts compared with patients in the vehicle group (Fig  3) . The mean changes in inflammatory lesion counts from baseline were À19.3 (95% confidence interval [CI] À22.3 to À16.4) and À13.3 (95% CI À16.0 to À10.5) for the OG and vehicle groups, respectively (P = .0003), corresponding to 63.9% and 45.9% fewer inflammatory lesions at week 12 compared with baseline in the 2 treatment groups, respectively (P = .0006). The mean changes in noninflammatory lesion counts from baseline were À19.9 (95% CI À25.2 to À14.6) and À11.2 (95% CI À15.7 to À6.7) for the OG and vehicle groups, respectively (P = .0032), corresponding to 48.1% and 28.8% fewer noninflammatory lesions at week 12 in the 2 treatment groups, respectively (P = .0025).
Treatment differences in lesion counts were observed at the first assessment time (ie, week 4). The OG group had greater reductions in inflammatory and noninflammatory lesions than the vehicle group, which was statistically significant for noninflammatory lesions (Fig 3) .
Greater improvements in IGA score (indicating less severe acne) were observed with OG than with vehicle. At week 12, more patients in the OG group had greater than or equal to 2-grade improvement compared with vehicle (24.5% vs 7.3%; P = .0070) (Fig 4) .
During treatment, 60.4% and 65.5% of patients in the OG and vehicle groups had a treatmentemergent AE. Common AEs were nasopharyngitis, application-site dryness, and application-site pain in both treatment groups, and application-site erythema in the OG group (Table II) . Most AEs were mild or moderate in severity; however, severe AEs were reported for 5 patients in the OG group J AM ACAD DERMATOL VOLUME 76, NUMBER 1 (application-site pain, application-site erythema, and nephrolithiasis) and 1 patient in the vehicle group (application-site dryness). The AEs most often considered related to study drug were applicationsite reactions (eg, erythema, pain, dryness). Study drug was discontinued because of application-site AEs (erythema, dryness, and pain) for 2 patients in the OG group and acne breakout for 1 patient in the vehicle group. Safety laboratory tests and vital signs remained stable throughout the study.
Mean local skin reaction scores at all time points indicated no reaction or a mild reaction. However, 5 patients, all treated with OG, had a severe reaction; 4 patients had severe burning/stinging and 1 patient had severe erythema. All severe local skin reactions were considered related to OG and all resolved without intervention.
DISCUSSION
OG inhibited synthesis for the majority of fatty acid components comprising sebum (eg, triglycerides, wax esters) in human sebocyte cultures. 12 Further, topically applied OG reproducibly reduced sebaceous gland size in animal models. 12 This Fig 2. Patient disposition. IGA, Investigator global assessment. *One subject in the vehicle group had no postbaseline efficacy assessments. The subject was not included in analyses of changes from baseline in lesion counts, but was included in analyses of changes in IGA score for which the subject was considered to have no change in IGA score. suggests that OG could provide a treatment option with a novel mechanism of action for patients with moderate to severe acne. Patients treated with OG had statistically significant improvements in acne: reduced inflammatory and noninflammatory lesions, and IGA scoring. The qualitative decrease in IGA scores of 2 or more grades correlated with the lesion count reductions. Patients receiving OG had greater reductions from baseline in inflammatory lesions (;18%) and in noninflammatory lesions (;19%) than vehicletreated patients. A lesion count difference of 10% or more between 2 therapeutic options in clinical trials has been characterized as clinically relevant. 13 Current US and European treatment guidelines recommend restricted use of antibiotics to limit emergence of resistant strains of P acnes. 13, 14 Although oral antibiotics are recommended for limited duration, topical antibiotic monotherapy is to be avoided and topical antibiotics should be used in combination with other topical agents (eg, retinoids, benzoyl peroxide) for a predefined duration. 13 Combination therapy has become a first-line approach to the treatment of acne 14 because drugs with differing mechanisms of action typically result in greater efficacy. 1, [14] [15] [16] This study showed that topically administered OG monotherapy was efficacious, showing clinical improvements similar to Treatment-emergent was defined as an AE that started on or after the first application of study drug and on or before the end of treatment. AE, Adverse event; MedDRA, Medical Dictionary for Regulatory Activities; OG, olumacostat glasaretil.
those reported for combination products, and was well tolerated.
